Didem Tuba AKÇALI, Doğa VURALLI, Hacer DOĞANAY AYDIN, Hayrunnisa BOLAY

Metoclopramide inhibits trigeminovascular activation: evidence for effective acute attack treatment in migraine

Background/aim: Metoclopramide is an effective and commonly used medication in acute migraine treatment but an experimental evidence base is lacking. We aimed to investigate the antimigraine effect of metoclopramide in a migraine model and whether the analgesic effect of metoclopramide was likely to be D2receptor-mediated. Materials and methods: Cortical spreading depression (CSD) was used to model migraine in adult male Wistar rats. Five CSDs were induced by pinprick. Metoclopramide (two different doses), raclopride, or 0.9% saline were administered 30 min before CSD induction. Two hours after the experiments, brain tissues were examined for c-fos activation. Results: In metoclopramide groups brain stem c-fos expression was significantly lower than in the CSD side of the saline group (P = 0.002). In the raclopride group, ipsilateral brain stem c-fos expression was also lower than in the saline group (P = 0.002). No difference in c-fos expression in the ipsilateral trigeminal nucleus caudalis between the raclopride and metoclopramide groups was observed (P > 0.05). Conclusion: Metoclopramide is shown to suppress trigeminovascular activation for the first time, providing an experimental basis for its role in migraine. The analgesic effect of metoclopramide is likely to be mediated by D2receptors since raclopride, a selective D2 receptor antagonist, suppresses trigeminovascular activation similarly

PDF

___

1. Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004; 329: 1369-1373.
2. Richer L, Graham L, Klassen T, Rowe B. Emergency department management of acute migraine in children in Canada: a practice variation study. Headache 2007; 47: 703-710.
3. Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003; 43: 729-733.
4. Bolay H, Durham P. Biological sciences for headache; pharmacology. In: Nappi G, Moskowitz M, editors. Headache: Handbook of Clinical Neurology Series. Vol. 97. Amsterdam, the Netherlands: Elsevier; 2010. pp. 47-71.
5. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-981.
6. Friedman BW, Esses D, Solorzano C, Dua N, Greenwald P, Radulescu R, Chang E, Hochberg M, Campbell C, Aghera A et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med 2008; 52: 399-406.
7. Eken C. Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis. Am J Emerg Med 2015; 33: 331-337.
8. Bolay H, Reuter U, Dunn AK, Huang ZH, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136-142.
9. Tepe N, Filiz A, Dilekoz E, Akcali D, Sara Y, Charles A, Bolay H. The thalamic reticular nucleus is activated by cortical spreading depression in freely moving rats: prevention by acute valproate administration. Eur J Neurosci 2015; 41: 120-128.
10. Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia 2007; 27: 1308-1314.
11. Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G. Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 1991; 14; 91- 95.
12. Bès A, Dupui P, Güell A, Bessoles G, Géraud G. Pharmacological exploration of dopamine hypersensitivity in migraine patients. Int J Clin Pharmacol Res 1986; 6: 189-192.
13. Amery WK, Waelkens J. Prevention of the last chance: an alternative pharmacologic treatment of migraine. Headache 1983; 23: 37-38.
14. Akerman S, Goadsby PJ. The role of dopamine in a model of trigeminovascular nociception. J Pharmacol Exp Ther. 2005; 314: 162-169.
15. Walkembach J, Brüss M, Urban BW, Barann M. Interactions of metoclopramide and ergotamine with human 5-HT3A receptors and human 5-HT reuptake carriers. Br J Pharmacol 2005; 146: 543-552.
16. Schwarzberg MN. Application of metoclopramide specificity in migraine attacks therapy. Headache 1994; 34: 439-441.